Huahai Pharma Cuts Private Placement Target by Half; Novartis to Acquire Anthos Therapeutics for Over $3 Billion
Huahai Pharmaceutical
Medical and Health Product Provider
VISEN
Endocrine-related Disease Treatment Drug Developer
Johnson & Johnson
Medical Device R&D and Manufacturer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Private placement is not easy.
On February 11, Huahai Pharmaceutical Co., Ltd. announced that it would adjust the scale of funds raised from a private placement of shares, reducing it from no more than 1.21 billion yuan (inclusive) to no more than 600 million yuan (inclusive). The proposed amount of funds for the projects has also been adjusted accordingly.
In short, the amount of Huahai Pharmaceutical's private placement has halved.
Novartis Buys and Buys.
On February 11, Novartis announced that it had reached an agreement to acquire Anthos Therapeutics. According to the terms of the agreement, Novartis will pay an upfront payment of $925 million upon completion of the transaction, subject to certain customary adjustments, and may pay up to an additional $2.15 billion upon achieving specified regulatory and sales milestones.
Anthos, a Boston-based clinical-stage biopharmaceutical company, is developing abelacimab, a late-stage drug targeting clotting factors FXI/FXIa for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) 3D Medicines Appoints Chief Commercial Officer
On February 10, 3D Medicines announced the appointment of Ding Gan as the company's Chief Commercial Officer, primarily responsible for product commercialization-related work. Previously, Ding Gan served as the Chief Executive Officer of Nian Yan Pharmaceuticals (Shanghai) Co., Ltd. and Contingent Biotechnology Co., Ltd., mainly in charge of the overall operation and management of the companies.
/ 02 /
Capital Information
1) Huahai Pharmaceutical Adjusts Private Placement Fundraising Amount from No More Than 1.21 Billion Yuan to No More Than 600 Million Yuan
On February 11, Huahai Pharmaceutical Co., Ltd. announced that it would adjust the scale of funds raised from a private placement of shares, reducing the amount from no more than 1.21 billion yuan (inclusive) to no more than 600 million yuan (inclusive). The company also made corresponding adjustments to the planned investment amounts for the projects.
2) VISEN Pharmaceuticals Passes HKEX Listing Hearing
On February 9, according to the Hong Kong Stock Exchange's official website, VISEN has passed the Hong Kong Stock Exchange listing hearing and is about to go public. VISEN was established in November 2018 as a late-stage biopharmaceutical company with products nearing commercialization, focusing on providing treatment solutions for specific endocrine disorders in China.
/ 03 /
Pharmaceutical News
1) Avivia Pharma Announces Top-Line Results of Phase 1/2 Clinical Trial for New Dry Eye Drug
On February 10, Aiva Pharmaceuticals announced positive topline data from the Phase 1/2 clinical trial of IVW-1001 for the treatment of dry eye disease. The data showed that IVW-1001 demonstrated good tolerability across all treatment groups, with most adverse events (AEs) being mild or moderate.
2) Johnson & Johnson's EGFR/MET Bispecific Antibody Approved for Marketing
On February 11, Johnson & Johnson announced that the NMPA had approved EGFR/MET bispecific antibody Rybrevant (Amivantamab) for use in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an approved test.
3) Johnson & Johnson's GPRC5D×CD3 bispecific antibody approved for marketing
On February 11, Johnson & Johnson announced the approval and market launch of Talquetamab, a GPRC5D×CD3 bispecific antibody, as a monotherapy for adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy.
4) MSD's combination antibiotic therapy approved for marketing
On February 11, according to the NMPA website, Merck's compound antibacterial drug, cefuroxime axetil and tazobactam sodium for injection, has been approved for marketing.
/ 04 /
Instrument Tracking
1) JINGZHUN Medical Gene Sequencer Not Registered
On February 11, according to the NMPA website, Jingzhun Medical's gene sequencer was not registered.
2) TiZhengHang Medical Orthopedic Surgical Navigation and Positioning System Obtains Registration Approval
On February 11, according to the NMPA website, TiRobot Healthcare's orthopedic surgery navigation and positioning system received registration approval.
3) Cortea Bio's Cross-linked Sodium Hyaluronate Gel for Injection Receives Registration Approval
On February 11, according to the NMPA website, Keteng Bio's cross-linked sodium hyaluronate gel for injection obtained registration approval.
4) ZhenGu Biologics' KRAS/BRAF/PIK3CA Gene Mutation Analysis Software Obtains Registration Approval
On February 11, according to the NMPA website, ZhenGu Biotech's KRAS/BRAF/PIK3CA Gene Mutation Analysis Software obtained registration approval.
/ 05 /
Overseas Pharma News
1) Novartis Acquires Anthos for Over $3 Billion
On February 11, Novartis announced that it had reached an agreement to acquire Anthos Therapeutics. According to the terms of the agreement, Novartis will pay an upfront payment of $925 million upon completion of the transaction, subject to certain customary adjustments, and may pay up to an additional $2.15 billion upon reaching specified regulatory and sales milestones. Anthos is a Boston-based clinical-stage biopharmaceutical company developing abelacimab, a late-stage drug targeting clotting factors FXI/FXIa for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
PS: Welcome to scan the QR code below to add Amino's WeChat ID for communication.
